Canntab Nears Commercialization with Innovative Cannabis Tablets

The global cannabis industry is projected to reach $146.4 billion by 2025, according to Grand View Research, representing a blistering 34.6 percent compound annual growth rate. With medical and adult-use legalization across a growing number of countries, there’s an enormous opportunity for innovative companies to become established market leaders and patients to access new life-changing medications.

A key problem facing the medical cannabis industry is dosing and consistency. Unlike pharmaceuticals, medical cannabis is typically prescribed in a smokable form that can produce inconsistent effects between patients. Many pharmaceuticals also offer extended release and features that can make the medicine more efficacious.

Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1) is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable, for physicians and their patients benefit. Investors may want to take a closer look at the company given its robust product portfolio and growing distribution network.

Strong Product Portfolio

Canntab has made tremendous progress building an intellectual property portfolio with 13 patents pending in the United States and Canada related to its formulations of cannabis tablets, including instant release, extended release, flash melt, and bi-layer products available in 2.5mg, 5mg, and 10mg tablets. These products will address a key shortcoming in cannabis-based medications—a lack of precise, dose-controlled formats supported by pharmacokinetic, dosing, and clinical data to ensure safety and efficacy.

Last year, the company announced an exclusive agreement with Emblem Corp. (TSX-V: EMC) to develop cannabis-based oral sustained release formulations. The partnership received Health Canada’s approval for research and development activities, and dissolution testing showed that the extended release tablets delivered cannabinoids consistently over a 12-hour period. The team plans to file dossiers with regulatory agencies around the world.

In addition to these agreements, Health Canada recently approved the company’s 420 Therapeutics brand of cannabis wellness capsules that are made from purified organic hemp seed oil. These capsules are an easy and convenient way to realize the health benefits of hemp oil, while setting the stage for the company’s long-term goal of manufacturing full spectrum hemp-derived cannabidiol (CBD) oil.

Joint Venture Distribution

Canntab has signed a number of joint venture agreements around the world to distribute its products to patients across many jurisdictions.

The company announced a non-binding letter of intent with NewCanna SAS of Bogota, Colombia to establish a significant bilateral relationship for the sale and distribution of its products. Under the agreement, NewCanna will distribute products across Colombia, Chile, Paraguay, and Spain in exchange for a one-time, non-refundable license fee of $2 million payable to Canntab after the agreement is finalized.

More recently, the company announced a non-binding letter of intent with Labsco Promedic SA of Monterrey, Mexico to establish a new distribution channel in Mexico. Under the terms of the agreement, the companies will work together to formalize a joint venture before the end of the year and launch products within the next five years. Mexico could become a significant market given the government’s recent liberalization of cannabis laws.

Looking Ahead

Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1) is rapidly approaching commercialization with new distribution channels in place. In addition, the company recently filed an application to become a licensed producer under Health Canada’s ACMPR program. If approved, the new designation would enable the company to manufacture products at its current production facility with minimal additional capital expenditure as compared to a new purpose-built facility.

With an excellent cap structure and no need for short-term financing, investors may want to take a closer look at the company as it gears up for commercialization. The potential approval of its tablets and new license from Health Canada could prove to be significant catalysts, while new joint venture agreements could pave the way to near-term income.

For more information, visit the company’s website at www.canntab.ca.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.